Keros Therapeutics, Inc. completed a tender offer that repurchased 10,950,165 shares of its common stock at a fixed price of $17.75 per share, totaling approximately $194.4 million. The offer, which expired at 5:00 p.m. ET on November 18, 2025, was fully accepted and represents roughly 35.9 % of the company’s outstanding shares.
Continue reading for full analysis...